Brief: Sienna Biopharmaceuticals Says Sna-001 In Acne Trials Did not Meet Primary, Secondary Endpoints

Sienna Biopharmaceuticals

30/07/2018 12:41

July 30 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O :
    * SIENNA BIOPHARMACEUTICALS ANNOUNCES PIVOTAL TRIALS WITH
SNA-001
IN ACNE DID NOT MEET PRIMARY AND SECONDARY ENDPOINTS
    * SIENNA BIOPHARMACEUTICALS INC - SIENNA CONTINUES TO
ADVANCE
ROBUST MULTI-ASSET PIPELINE, INCLUDING SNA-120 AND SNA-125
    * SIENNA - RESULTS FROM INDEPENDENT PIVOTAL TRIALS WITH
SNA-001
FOR REDUCTION OF UNWANTED LIGHT-PIGMENTED HAIR EXPECTED
BEGINNING IN Q4 OF 2018
    * SIENNA - RESULTS FROM THIRD, INDEPENDENT PIVOTAL TRIAL IN
ACNE
USING SNA-001 IN CONJUNCTION WITH 755 NM LASER EXPECTED IN Q4
2018

Source text for Eikon:  ID:nGNXbgwLbQ 
Further company coverage:  SNNA.O 

 ((Briefs@thomsonreuters.com;))